Ecopia BioSciences Inc. (TSX:EIA) held today its Annual General Meeting of Shareholders at the McGill Faculty Club & Conference Centre in Montreal. Dr. Pierre Falardeau, President and Chief Executive Officer of Ecopia, told shareholders: “During the last year, an important milestone has been achieved as we have successfully progressed from being a preclinical development company to a clinical stage company. This new positioning is of great importance, as it will allow us to move forward in establishing proof of principle in humans for our first clinical candidate, ECO-4601. This advancement further validates the power of our DECIPHER® technology to deliver potential drugs from nature.”
